Eli Lilly and Company (NYSE:LLY) Shares Down 3.4% – Time to Sell?

Eli Lilly and Company (NYSE:LLY) shares fell 3.4% on Wednesday . The company traded as low as $1,180.01 and last traded at $1,191.49. Approximately 2,977,720 shares traded hands during trading, a decline of 4% from the average session volume of 3,090,131 shares. The stock had previously closed at $1,233.66.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A real-world study found that adults over 55 who continued using Zepbound experienced fewer hospitalizations and emergency-room visits, resulting in lower healthcare costs. The findings could support broader payer adoption and the Medicare GLP-1 Bridge program. Zepbound real-world study
• Positive Sentiment: Lilly and Roche received FDA clearance for an Alzheimer’s blood test, expanding potential diagnostic tools connected to the Alzheimer’s market. The test had previously been approved in Europe. Alzheimer’s blood test FDA clearance
• Positive Sentiment: Lilly is expanding its Alzheimer’s pipeline with a new Phase 1 amyloid-targeting study. While early-stage, the program adds to the company’s longer-term growth opportunities alongside Kisunla. Lilly Alzheimer’s Phase 1 trial
• Positive Sentiment: Citadel founder Ken Griffin reportedly nearly quadrupled his Lilly position during the second quarter, signaling continued institutional confidence in the company’s obesity-drug franchise and broader pipeline. Ken Griffin increases Lilly stake
• Neutral Sentiment: Foundayo’s launch in the United Kingdom gives Lilly’s oral obesity-drug franchise another international market, although the financial impact will depend heavily on reimbursement and pricing. Foundayo UK launch
• Negative Sentiment: Employers are becoming more selective about covering GLP-1 weight-loss medicines. Reports that PepsiCo’s health plan will remove coverage for certain obesity drugs have intensified concerns that payer restrictions could slow Zepbound and Foundayo volume growth. GLP-1 coverage concerns
• Negative Sentiment: After a strong run and elevated valuation, investors appear to be taking profits. Recent insider activity also shows several Lilly executives selling shares, which may add to short-term sentiment pressure, though it does not necessarily indicate a change in fundamentals. Lilly stock pullback

Analyst Upgrades and Downgrades

Several analysts recently commented on LLY shares. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a report on Friday, August 7th. Barclays raised their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Weiss Ratings cut shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 11th. Finally, Leerink Partners raised their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,292.18.

Eli Lilly and Company Stock Down 3.4%

The company has a 50-day moving average of $1,184.69 and a two-hundred day moving average of $1,062.54. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market capitalization of $1.12 trillion, a PE ratio of 39.98, a P/E/G ratio of 1.47 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter in the prior year, the business posted $6.31 earnings per share. The business’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 23.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 over the last 90 days. 0.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System grew its position in shares of Eli Lilly and Company by 120,133.2% during the second quarter. California State Teachers Retirement System now owns 1,460,379,190 shares of the company’s stock worth $1,751,622,612,000 after purchasing an additional 1,459,164,568 shares in the last quarter. Norges Bank purchased a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $12,976,634,000. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $13,522,666,000. J. Stern & Co. LLP lifted its holdings in shares of Eli Lilly and Company by 46,191.3% in the fourth quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after buying an additional 4,038,502 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new position in shares of Eli Lilly and Company in the second quarter worth $4,667,180,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.